Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1212/CPJ.0000000000000239 http://scihub22266oqcxt.onion/10.1212/CPJ.0000000000000239 C4828678!4828678!27104068     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Neurol+Clin+Pract 2016 ; 6 (2): 164-76 Nephropedia Template TP {{tp|p=27104068|t=2016. Clinical exome sequencing in neurologic disease: AAN model coverage policy |pdf=|usr=}}{{27104068}} gab.com Text Clinical exome sequencing in neurologic disease: AAN model coverage policy JO: Neurol Clin Pract http://www.kidney.de/pget.php?&tw=1&pmid=27104068 #FOAvip Purpose of review:: The landscape of genetic diagnostic testing has changed dramatically with the introduction of next-generation clinical exome sequencing (CES), which provides an unbiased analysis of all protein-coding sequences in the roughly 21,000 genes in the human genome. Use of this testing, however, is currently limited in clinical neurologic practice by the lack of a framework for appropriate use and payer coverage. Recent findings:: CES can be cost-effective due to its high diagnostic yield in comparison to other genetic tests in current use and should be utilized as a routine diagnostic test in patients with heterogeneous neurologic phenotypes facing a broad genetic differential diagnosis. CES can eliminate the need for escalating sequences of conventional neurodiagnostic tests. Summary:: This review discusses the role of clinical exome sequencing in neurologic disease, including its benefits to patients, limitations, appropriate use, and billing. We also provide a reference template policy for payer use when considering testing requests. Twit Text FOAVip Clinical exome sequencing in neurologic disease: AAN model coverage policy ????Neurol Clin Pract http://www.kidney.de/pget.php?&tw=1&pmid=27104068 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27104068 #FOAvip English Wikipedia <ref>{{Cite pmid|27104068}}</ref> Clinical exome sequencing in neurologic disease: AAN model coverage policy #MMPMID27104068 Fogel BL; Satya-Murti S; Cohen BH Neurol Clin Pract 2016[Apr]; 6 (2): 164-76 PMID27104068show ga Purpose of review:: The landscape of genetic diagnostic testing has changed dramatically with the introduction of next-generation clinical exome sequencing (CES), which provides an unbiased analysis of all protein-coding sequences in the roughly 21,000 genes in the human genome. Use of this testing, however, is currently limited in clinical neurologic practice by the lack of a framework for appropriate use and payer coverage. Recent findings:: CES can be cost-effective due to its high diagnostic yield in comparison to other genetic tests in current use and should be utilized as a routine diagnostic test in patients with heterogeneous neurologic phenotypes facing a broad genetic differential diagnosis. CES can eliminate the need for escalating sequences of conventional neurodiagnostic tests. Summary:: This review discusses the role of clinical exome sequencing in neurologic disease, including its benefits to patients, limitations, appropriate use, and billing. We also provide a reference template policy for payer use when considering testing requests. äClinical exome sequencing in neurologic disease: AAN model coverage po(epmc).pdf DeepDyve Pubget Overpricing